Based on our current knowledge, one of the mechanisms of action of lovastatin is inhibition of IL‐2 production with reduction in the level of systemic inflammation in patients with atherosclerosis62 with potential therapeutic implications in patients with AF. The gene discussed is IL2; the disease is atrial fibrillation.